2026 Outlook on the Management of Drug Price Negotiation Program and Competitor Drugs
Magnolia Market Access released its fifth iteration of the IRA Payer Insights Survey in the summer of 2025 to understand how the IRA will affect the Medicare Part D program, including beneficiary premiums, formulary coverage, and contract negotiations for manufacturers and payers. The survey includes insights from 17 medical and pharmacy directors from national and regional payers, and pharmacy benefit managers, accounting for over 250 million covered lives.
Key Findings include:
- Part D plans anticipated actions for CY 2026 as a result of the IRA Drug Price Negotiation Program (DPNP) and the Centers for Medicare & Medicaid Services (CMS) established maximum fair price (MFP)
- The evolution of utilization management (UM) tools for negotiated and non-negotiated products in Medicare Part D plans in 2026
Download now to gain insights into anticipated use of utilization management in CY2026 in response to MFP negotiations.
